There are 2137 resources available
691TiP - A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status
Presenter: Ugo De Giorgi
Session: E-Poster Display
Resources:
Abstract
692TiP - BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Carlo Cattrini
Session: E-Poster Display
Resources:
Abstract
693TiP - LOBSTER LOng term Better than Short-TErm ADT with salvage radiotherapy
Presenter: Charlien Berghen
Session: E-Poster Display
Resources:
Abstract
694TiP - DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
Presenter: Tamim Niazi
Session: E-Poster Display
Resources:
Abstract
695TiP - ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to characterize the prostate cancer pathway, management and outcomes in Europe, Middle East and Africa (EMEA region)
Presenter: Joan Carles
Session: E-Poster Display
Resources:
Abstract
709P - Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study
Presenter: Bradley McGregor
Session: E-Poster Display
Resources:
Abstract
710P - Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
Presenter: Chung-Han Lee
Session: E-Poster Display
Resources:
Abstract
711P - Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Presenter: Laurence Albiges
Session: E-Poster Display
Resources:
Abstract
712P - Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial
Presenter: Jean Courcier
Session: E-Poster Display
Resources:
Abstract
713P - Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214
Presenter: Meredith Regan
Session: E-Poster Display
Resources:
Abstract